WEBINAR: Metabolomics Connects the Genome to Phenotype
Understanding phenotypes is the central need for enabling research and medical advances. The exploration of gene function and the use of genomics tools have been a focal-point for unraveling phenotypes for the last 2 decades. But, while these genomic tools have provided many important insights and discoveries a staggeringly complex picture has also emerged. Deciphering the meaningful biological signal from noise amongst all of this complexity is a persistent challenge.
Since metabolites are regarded as an intermediate phenotype, metabolomics has emerged as an ideal way to bridge the genotype-phenotype relationship. However, there are critical considerations to successful implementation of metabolomics; platforms must be highly stable, scalable and able to capture a meaningfully broad swath of the metabolites within a biological sample.
The webinar will review the history of phenotyping with genomic approaches and outline some of the key challenges and how, since metabolites provide an “intermediate phenotype” metabolomics has become an important companion. We will also detail some of the key technological hurdles that were overcome in order for metabolomics to contribute to defining intermediate phenotypes and, hence, gene activity and function. Finally, we will summarize how metabolomics is contributing to human genetics, transcriptional profiling and microbiome research.
- History of phenotyping with genomic approaches
- Key challenges
- Key technology hurdles overcome with metabolomics
- Summary of how metabolomics is contributing to human genetics, transcriptional profiling and microbiome research
Join us for Metabolomics Connects the Genome to Phenotype on May 23rd 2017 at 10:30 AM EDT (3:30 PM BST / 7:30 AM PDT)
John Ryals (Ph.D.) | Metabolon
President and Chief Executive Officer
Dr. Ryals has served as President, CEO and a member of the board of directors at Metabolon since April 2002. Prior to founding Metabolon, he was Chief Executive Officer, President and founder of Paradigm Genetics, Inc., a publicly traded agricultural biotechnology company focused on industrializing the process of gene function discovery. Dr. Ryals has 30 years of experience in the biotechnology industry, including senior research positions at Novartis and Ciba-Geigy. He currently serves on the board of directors at AgBiome, a provider of early-stage R&D for agriculture, and the advisory board of the College of Agriculture and Life Sciences at North Carolina State University. He earned a B.A. in biology and chemistry from the University of North Texas and M.S. and Ph.D. degrees in molecular biology from the University of Texas at Dallas.
Metabolon, Inc. is the world’s leading health technology company advancing metabolomics for precision medicine and all areas of life sciences research. Its Precision Metabolomics™ is a powerful technology for assessing health and is delivering biomarker discoveries, innovative diagnostic tests, and ground-breaking partnerships in genomics and population health initiatives. Metabolon’s expertise is also accelerating research and product development across the pharmaceutical, biotechnology, consumer products, agriculture and nutrition industries, as well as academic and government organizations. The company was founded in 2000 and is headquartered in Research Triangle Park, North Carolina.